Recent advances in bioengineering and manufacturing have catapulted Antibody–drug conjugates (ADCs) to broader clinical applications. ADCs take advantage of the exquisite specificity of monoclonal antibodies (mAb) to deliver a highly potent cytotoxic agent to a specifically targeted cell expressing a selected antigen. HER2-positive breast cancer has served as a testing ground for ADC development in solid tumors that over-express HER2/neu by linking trastuzumab to a payload agent. With the current advances, ADCs leverage the selective targeting of monoclonal antibodies to deliver highly potent agents which otherwise have a narrow therapeutic index. Ado-trastuzumab emtansine (T-DM1) was the first ADC approved for patients with HER2-postive metastatic breast cancer (MBC) and fam-trastuzumab deruxtecan-nxki (T-DXd) was recently approved as well. Sacituzumab govitecan-hziy (SG) was approved in 2020 for patients with triple negative breast cancer (TNBC). Studies focusing on utilizing ADCs in earlier stages of breast cancer in the neoadjuvant or adjuvant setting, and central nervous system (CNS) disease are in progress. New ADCs and bispecific antibodies (bAbs) are also in development.
{"title":"Antibody drug conjugates (ADCs): an expanding rational treatment paradigm in breast cancer","authors":"Fengting Yan, Lian Sun, Aimee Wu, H. Kaplan","doi":"10.53876/001c.33661","DOIUrl":"https://doi.org/10.53876/001c.33661","url":null,"abstract":"Recent advances in bioengineering and manufacturing have catapulted Antibody–drug conjugates (ADCs) to broader clinical applications. ADCs take advantage of the exquisite specificity of monoclonal antibodies (mAb) to deliver a highly potent cytotoxic agent to a specifically targeted cell expressing a selected antigen. HER2-positive breast cancer has served as a testing ground for ADC development in solid tumors that over-express HER2/neu by linking trastuzumab to a payload agent. With the current advances, ADCs leverage the selective targeting of monoclonal antibodies to deliver highly potent agents which otherwise have a narrow therapeutic index. Ado-trastuzumab emtansine (T-DM1) was the first ADC approved for patients with HER2-postive metastatic breast cancer (MBC) and fam-trastuzumab deruxtecan-nxki (T-DXd) was recently approved as well. Sacituzumab govitecan-hziy (SG) was approved in 2020 for patients with triple negative breast cancer (TNBC). Studies focusing on utilizing ADCs in earlier stages of breast cancer in the neoadjuvant or adjuvant setting, and central nervous system (CNS) disease are in progress. New ADCs and bispecific antibodies (bAbs) are also in development.","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127051247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junid A. Naveed Ahmad, Bowen He, B. Schroeder, J. Rosales
Lung cancer remains the most common cause of cancer-related deaths worldwide, with Non-Small Cell Lung Cancer (NSCLC) the predominant histologic subtype. Increasingly, molecular mutations are identified and used as therapeutic targets. We describe the case of a woman diagnosed with locally metastatic NSCLC, and distinct pulmonary masses, later identified as two independent primary lung tumors based on molecular profiling. A 58-year-old-female presented with cough and hemoptysis. Chest Computed Tomography (CT) revealed a 4.3cm mass in the right lung apex, 2.0 cm nodule in the right lower lobe (RLL), and right paratracheal/hilar adenopathy. Subsequent Positron Emission Tomography-Computed Tomography (PET-CT) showed uptake in the right upper lobe (RUL) (SUV 12.2) and RLL (standard uptake value (SUV) 2.5) masses and mediastinal lymph nodes, but no distant metastases. Bronchoscopic biopsy of the RUL mass and 4R lymph node were positive for poorly differentiated adenocarcinoma, and molecular analysis revealed Epidermal Growth Factor Receptor (EGFR) L858R mutation. Subsequent Electromagnetic Navigation (EMN) biopsy of the RLL lesion also showed adenocarcinoma, but with an EGFR exon-19 deletion. Both were negative for T790M mutation. She was therefore diagnosed with two separate primaries instead of intrathoracic metastases. She started erlotinib and after 4 months, repeat PET-CT showed complete response (CR) in the RLL and partial response (PR) in the RUL. Decision was made to pursue surgery with RUL/RLL bilobectomy. Pathology showed evidence of N2 disease; therefore, at time of surgery she was stage IIIA, presumably from the RUL mass. The RLL mass was presumed to be stage I. These were successfully resected, and she was deemed to have no evidence of disease (NED) post-operatively. Although co-mutations within the same tumor have been reported in up to 12% of patients,28 we are not aware of other cases in which a single patient was diagnosed with two separate primary lung tumors based on genetic profiles. Consequently, she was able to be treated with curative rather than palliative intent.
{"title":"Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report","authors":"Junid A. Naveed Ahmad, Bowen He, B. Schroeder, J. Rosales","doi":"10.53876/001c.37213","DOIUrl":"https://doi.org/10.53876/001c.37213","url":null,"abstract":"Lung cancer remains the most common cause of cancer-related deaths worldwide, with Non-Small Cell Lung Cancer (NSCLC) the predominant histologic subtype. Increasingly, molecular mutations are identified and used as therapeutic targets. We describe the case of a woman diagnosed with locally metastatic NSCLC, and distinct pulmonary masses, later identified as two independent primary lung tumors based on molecular profiling. A 58-year-old-female presented with cough and hemoptysis. Chest Computed Tomography (CT) revealed a 4.3cm mass in the right lung apex, 2.0 cm nodule in the right lower lobe (RLL), and right paratracheal/hilar adenopathy. Subsequent Positron Emission Tomography-Computed Tomography (PET-CT) showed uptake in the right upper lobe (RUL) (SUV 12.2) and RLL (standard uptake value (SUV) 2.5) masses and mediastinal lymph nodes, but no distant metastases. Bronchoscopic biopsy of the RUL mass and 4R lymph node were positive for poorly differentiated adenocarcinoma, and molecular analysis revealed Epidermal Growth Factor Receptor (EGFR) L858R mutation. Subsequent Electromagnetic Navigation (EMN) biopsy of the RLL lesion also showed adenocarcinoma, but with an EGFR exon-19 deletion. Both were negative for T790M mutation. She was therefore diagnosed with two separate primaries instead of intrathoracic metastases. She started erlotinib and after 4 months, repeat PET-CT showed complete response (CR) in the RLL and partial response (PR) in the RUL. Decision was made to pursue surgery with RUL/RLL bilobectomy. Pathology showed evidence of N2 disease; therefore, at time of surgery she was stage IIIA, presumably from the RUL mass. The RLL mass was presumed to be stage I. These were successfully resected, and she was deemed to have no evidence of disease (NED) post-operatively. Although co-mutations within the same tumor have been reported in up to 12% of patients,28 we are not aware of other cases in which a single patient was diagnosed with two separate primary lung tumors based on genetic profiles. Consequently, she was able to be treated with curative rather than palliative intent.","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130644377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. B. Kridis, O. Boudawara, Ameni Feki, N. Toumi, A. Khanfir
{"title":"Predict score and luminal localized breast cancer in young women","authors":"W. B. Kridis, O. Boudawara, Ameni Feki, N. Toumi, A. Khanfir","doi":"10.53876/001c.36948","DOIUrl":"https://doi.org/10.53876/001c.36948","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127612128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ellana Haakenstad, Jane E. Roberts, C. Lathan, O. Kozyreva, N. McCleary
{"title":"Barriers and facilitators to genomic testing uptake and cancer clinical trial enrollment in historically underrepresented patient populations - Clinician and research staff perceptions","authors":"Ellana Haakenstad, Jane E. Roberts, C. Lathan, O. Kozyreva, N. McCleary","doi":"10.53876/001c.36116","DOIUrl":"https://doi.org/10.53876/001c.36116","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"98 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115767132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prostate Cancer (PCa) in Male & Breast Cancer (BCa) in Female Make Largest Cancer Pool in the World & in the EU28+EFTA","authors":"A. R. Dahal","doi":"10.53876/001c.36112","DOIUrl":"https://doi.org/10.53876/001c.36112","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130144614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrea Curry, Gabriella Bufalino, Cheryl A. Prince, A. Dowdy, Cynthia Inman, Asif Kamal, Sonia Benn, G. Vidal
{"title":"An Evaluation of Health Disparities Among Breast Cancer Patients and the Relationship to Emergency Department Utilization","authors":"Andrea Curry, Gabriella Bufalino, Cheryl A. Prince, A. Dowdy, Cynthia Inman, Asif Kamal, Sonia Benn, G. Vidal","doi":"10.53876/001c.36119","DOIUrl":"https://doi.org/10.53876/001c.36119","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"148 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134321099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Treatment of advanced prostate cancer has improved rapidly in the past two decades with the introduction of many new therapeutics including several entirely new therapeutic classes. Whereas androgen deprivation therapy was previously the first and only line of treatment available, modern therapy also routinely employs second generation anti-androgens, chemotherapy, immunotherapy, radiopharmaceuticals, bone modifying agents, and poly(ADP-ribose) polymerase (PARP) inhibitors, with a resulting substantial increase in patient survival. This review aims to summarize the current treatment landscape for advanced prostate cancer, with a particular focus on hormone refractory (also known as ‘castration resistant’) prostate cancer (HRPC), and we hope will serve as a practical guide for clinicians and trainees.
{"title":"Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer","authors":"N. Younger, H. Borno","doi":"10.53876/001c.36780","DOIUrl":"https://doi.org/10.53876/001c.36780","url":null,"abstract":"Treatment of advanced prostate cancer has improved rapidly in the past two decades with the introduction of many new therapeutics including several entirely new therapeutic classes. Whereas androgen deprivation therapy was previously the first and only line of treatment available, modern therapy also routinely employs second generation anti-androgens, chemotherapy, immunotherapy, radiopharmaceuticals, bone modifying agents, and poly(ADP-ribose) polymerase (PARP) inhibitors, with a resulting substantial increase in patient survival. This review aims to summarize the current treatment landscape for advanced prostate cancer, with a particular focus on hormone refractory (also known as ‘castration resistant’) prostate cancer (HRPC), and we hope will serve as a practical guide for clinicians and trainees.","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122977200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of the Palliative Prognostic Index (PPI) in Cancer Patients","authors":"W. Ben Kridis","doi":"10.53876/001c.36367","DOIUrl":"https://doi.org/10.53876/001c.36367","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130079211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Epidemiological and clinical characteristics of male breast cancer in the south of Tunisia: A single center experience","authors":"W. Ben Kridis","doi":"10.53876/001c.36460","DOIUrl":"https://doi.org/10.53876/001c.36460","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133435461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
U. Joshi, A. Bhattarai, V. Agrawal, Uttam Bhetuwal, Anurag Adhikari, Prajwal Dhakal, V. Bhatt
{"title":"Factors Affecting Utilization Of Chemotherapy In Acute Lymphoblastic Leukemia (ALL): A SEER Database Study","authors":"U. Joshi, A. Bhattarai, V. Agrawal, Uttam Bhetuwal, Anurag Adhikari, Prajwal Dhakal, V. Bhatt","doi":"10.53876/001c.36148","DOIUrl":"https://doi.org/10.53876/001c.36148","url":null,"abstract":"","PeriodicalId":237891,"journal":{"name":"International Journal of Cancer Care and Delivery","volume":"47 9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131331123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：